Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Anabelle Maldonado-Medina

Neurology Miami, FL Medical Doctor

NPI 1609876804 CMS profile 466179

1190 Nw 95 Street, Suite 204, Miami, FL 33150

Open in the dashboard

General payments

$11,668

581 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anabelle Maldonado-Medina of Miami, FL is reported in the CMS Open Payments database as having received $11,668 across 581 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,537 72
2024 General $1,699 83
2023 General $1,547 77
2022 General $1,732 89
2021 General $2,452 133
2020 General $1,369 74
2019 General $1,331 53

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anabelle Maldonado-Medina
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Anabelle Maldonado-Medina were reported at $1,537. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Anabelle Maldonado-Medina Neurology median Middle half National median
2019 $1,331 $474 $118–$2,177 $163
2020 $1,369 $367 $82–$2,309 $114
2021 $2,452 $438 $104–$2,547 $132
2022 $1,732 $442 $103–$2,388 $149
2023 $1,547 $464 $119–$2,312 $160
2024 $1,699 $468 $119–$2,323 $164
2025 $1,537 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. UCB, Inc. $1,688 55 payments
  2. AbbVie, Inc. $1,340 75 payments
  3. ACADIA Pharmaceuticals Inc $997 53 payments
  4. SK Life Science, Inc. $917 37 payments
  5. Biohaven Pharmaceuticals, Inc. $702 46 payments
  6. Pfizer Inc. $690 37 payments
  7. Adamas Pharmaceuticals, Inc. $563 35 payments
  8. Eisai Inc. $471 22 payments
  9. Otsuka America Pharmaceutical, Inc. $442 21 payments
  10. Neurocrine Biosciences, Inc. $349 20 payments
  11. Other $3,509 180 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,540 570 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $93 5 payments
  3. Education $34 6 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $1,046 58 payments
  2. NURTEC ODT Primary Care $1,033 68 payments
  3. Vimpat $879 29 payments
  4. Briviact $787 25 payments
  5. QULIPTA $749 40 payments
  6. NURTEC ODT Pain $690 37 payments
  7. ZAVZPRET $582 32 payments
  8. GOCOVRI $563 35 payments
  9. NUPLAZID Parkinsons Disease Psychosis $534 32 payments
  10. NUPLAZID Parkinsons Disease Psychosis $463 21 payments
  11. Other $5,264 260 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 55 drugs

Part D claims

2,838

Median for Neurology: 833

Drug cost

$1,407,636

Median for Neurology: $202,670

Branded share of claims

22.1%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Skyclarys Omaveloxolone Brand 18 $587,417
Nuplazid Pimavanserin Tartrate Brand 83 $407,620
Rexulti Brexpiprazole Brand 49 $99,545
Copaxone Glatiramer Acetate Brand 11 $56,736
Neupro Rotigotine Brand 34 $36,931
Gocovri Amantadine Hcl Brand 21 $36,136
Rasagiline Mesylate Generic 158 $35,701
Xcopri Cenobamate Brand 19 $30,189
Nourianz Istradefylline Brand 14 $26,270
Qulipta Atogepant Brand 15 $17,625

The 10 drugs with the highest cost, of 55 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$23,385

Medicare's payments for the services billed

Medicare patients

65

Average age 69

Services billed

172

31 women, 34 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 46%
Arthritis 38%
Depression 35%
Alzheimer's or dementia 35%
Chronic kidney disease 28%
Ischemic heart disease 26%
Heart failure 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $212
  • Lundbeck LLC $28
$240 49 —
UBRELVY
  • AbbVie, Inc. $175
$175 — —
QULIPTA
  • AbbVie, Inc. $167
$167 15 —
NUPLAZID
  • ACADIA Pharmaceuticals Inc $166
$166 83 —
Leqembi
  • Eisai Inc. $128
$128 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

581 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record